Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) major shareholder Marlio Charles Mosseri bought 17,000 shares of the business's stock in a transaction on Friday, December 13th. The shares were acquired at an average cost of $4.70 per share, for a total transaction of $79,900.00. Following the purchase, the insider now directly owns 2,612,000 shares in the company, valued at $12,276,400. This represents a 0.66 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Major shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.
Nuvectis Pharma Price Performance
Shares of NVCT opened at $4.87 on Tuesday. Nuvectis Pharma, Inc. has a one year low of $4.52 and a one year high of $12.10. The stock's fifty day moving average is $6.52 and its 200-day moving average is $6.55.
Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.01. During the same quarter in the prior year, the business posted ($0.37) earnings per share. Research analysts anticipate that Nuvectis Pharma, Inc. will post -1.01 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Nuvectis Pharma
Could This Tiny Device Help You Make an Extra $30k a Year?
From Brownstone Research | Ad
I believe it’s going to power Elon Musk’s next AI revolution…
A revolution he believes will be worth more than $9 trillion.
That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.
Click here to see the details because I believe a lot of people will get rich.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. bought a new position in Nuvectis Pharma during the 2nd quarter valued at $58,000. Nations Financial Group Inc. IA ADV bought a new position in Nuvectis Pharma during the third quarter valued at about $63,000. GSA Capital Partners LLP grew its holdings in Nuvectis Pharma by 3.7% during the third quarter. GSA Capital Partners LLP now owns 50,129 shares of the company's stock worth $315,000 after acquiring an additional 1,790 shares during the period. Iridian Asset Management LLC CT bought a new stake in Nuvectis Pharma in the third quarter worth about $348,000. Finally, Renaissance Technologies LLC lifted its holdings in Nuvectis Pharma by 20.7% in the 2nd quarter. Renaissance Technologies LLC now owns 74,500 shares of the company's stock valued at $472,000 after acquiring an additional 12,800 shares during the last quarter. Institutional investors own 96.77% of the company's stock.
Nuvectis Pharma Company Profile
(
Get Free Report)
Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
